Literature DB >> 16231753

Diastolic dysfunction in hypertensive hearts: roles of perivascular inflammation and reactive myocardial fibrosis.

Hisashi Kai1, Fumitaka Kuwahara, Keisuke Tokuda, Tsutomu Imaizumi.   

Abstract

There is increasing evidence that myocardial fibrosis plays a role in the pathogenesis of diastolic dysfunction in hypertensive heart disease. However, it has been difficult to explore the mechanisms of isolated diastolic dysfunction in hypertensive hearts because of the lack of adequate animal models. Recently, we demonstrated that Wistar rats with a suprarenal aortic constriction (AC) can be used as a model of cardiac hypertrophy associated with preserved systolic, but impaired diastolic function without overt congestive heart failure. In this model, acute pressure elevation induces reactive myocardial fibrosis (perivascular fibrosis followed by intermuscular interstitial fibrosis) and myocyte/left ventricular (LV) hypertrophy. Perivascular macrophage infiltration, which is mediated by monocyte chemoattractant protein-1 (MCP-1) and intercellular adhesion molecule-1, exerts a key role in myocardial fibrosis, but not in myocyte/LV hypertrophy. Transforming growth factor (TGF)-beta is crucial for reactive fibrosis in AC rats. MCP-1 function blocking not only inhibits macrophage infiltration and TGF-beta induction but also prevents reactive fibrosis and diastolic dysfunction, without affecting blood pressure, myocyte/LV hypertrophy, or systolic function. Accordingly, a substantial role of inflammation is indicated in myocardial fibrosis and diastolic dysfunction in hypertensive hearts. Currently, the precise mechanisms whereby acute pressure elevation triggers inflammation remain unknown, but it is likely that activation of the tissue angiotensin system is involved in the induction of the inflammatory process.

Entities:  

Mesh:

Year:  2005        PMID: 16231753     DOI: 10.1291/hypres.28.483

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  53 in total

1.  Maternal obesity induces fibrosis in fetal myocardium of sheep.

Authors:  Yan Huang; Xu Yan; Jun X Zhao; Mei J Zhu; Richard J McCormick; Stephen P Ford; Peter W Nathanielsz; Jun Ren; Min Du
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-09-28       Impact factor: 4.310

2.  Moxonidine improves cardiac structure and performance in SHR through inhibition of cytokines, p38 MAPK and Akt.

Authors:  H Aceros; G Farah; L Cobos-Puc; A M Stabile; N Noiseux; S Mukaddam-Daher
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

3.  Omega-3 fatty acids prevent pressure overload-induced cardiac fibrosis through activation of cyclic GMP/protein kinase G signaling in cardiac fibroblasts.

Authors:  Jinghai Chen; Gregory C Shearer; Quanhai Chen; Chastity L Healy; April J Beyer; Vijaya B Nareddy; A Martin Gerdes; William S Harris; Timothy D O'Connell; Dajun Wang
Journal:  Circulation       Date:  2011-01-31       Impact factor: 29.690

4.  Discovery of vascular Rho kinase (ROCK) inhibitory peptides.

Authors:  Reza Abbasgholizadeh; Hua Zhang; John W Craft; Robert M Bryan; Steven J Bark; James M Briggs; Robert O Fox; Anton Agarkov; Warren E Zimmer; Scott R Gilbertson; Robert J Schwartz
Journal:  Exp Biol Med (Maywood)       Date:  2019-05-27

Review 5.  Molecular determinants of the cardiometabolic phenotype.

Authors:  Lisa de las Fuentes; Giovanni de Simone; Donna K Arnett; Víctor G Dávila-Román
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2010-06       Impact factor: 2.895

6.  Endothelial Nogo-B regulates sphingolipid biosynthesis to promote pathological cardiac hypertrophy during chronic pressure overload.

Authors:  Yi Zhang; Yan Huang; Anna Cantalupo; Paula S Azevedo; Mauro Siragusa; Jacek Bielawski; Frank J Giordano; Annarita Di Lorenzo
Journal:  JCI Insight       Date:  2016-04-21

7.  Histopathological study of time course changes in inter-renal aortic banding-induced left ventricular hypertrophy of mice.

Authors:  Hiroyuki Higashiyama; Masaki Sugai; Hirotaka Inoue; Kaori Mizuyachi; Hiroshi Kushida; Satoshi Asano; Mine Kinoshita
Journal:  Int J Exp Pathol       Date:  2007-02       Impact factor: 1.925

8.  Serum Amyloid P-Component Prevents Cardiac Remodeling in Hypertensive Heart Disease.

Authors:  Stephen J Horgan; Chris J Watson; Nadia Glezeva; Pat Collier; Roisin Neary; Isaac J Tea; Niamh Corrigan; Mark Ledwidge; Ken McDonald; John A Baugh
Journal:  J Cardiovasc Transl Res       Date:  2015-11-17       Impact factor: 4.132

9.  Estrogen therapy, independent of timing, improves cardiac structure and function in oophorectomized mRen2.Lewis rats.

Authors:  Jewell A Jessup; Hao Wang; Lindsay M MacNamara; Tennille D Presley; Daniel B Kim-Shapiro; Lili Zhang; Alex F Chen; Leanne Groban
Journal:  Menopause       Date:  2013-08       Impact factor: 2.953

10.  Meta-analysis and profiling of cardiac expression modules.

Authors:  Uri David Akavia; Dafna Benayahu
Journal:  Physiol Genomics       Date:  2008-09-09       Impact factor: 3.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.